MEDIGENE

Welcome to the Brand page for “MEDIGENE”, which is offered here for The mark consists of the wording medigene in stylized script, where the letter i is comprised of two oval shapes.;pharmaceutical and veterinary preparations, cellular preparations for the treatment of tumours/neoplastic diseases, hematological tumors, more specifically leukemias or lymphomkas, solid tumors; pharmaceutical t-cell preparations and dendritic cell preparations for the treatment of cancer and use in immunotherapy; medical compositions in the nature of pharmaceutical preparations for the treatment of hematological and solid tumors, tumor precursors; test kits for diagnostic preparations for medical purposes for determining the type and/or existence of a tumor in a patient consisting primarily of soluble t-cell receptors; test kits for diagnostic preparations for medical purposes for determining the type and/or existence of a tumor in a patient consisting primarily of genetically modified cells; test kits for diagnostic preparations for medical purposes for determining the type/existence of a tumor in a patient consisting of a composition of antibodies, soluble t-cell receptors and genetically modified cells; diagnostic and therapeutic preparations for medical purposes being mixtures of therapeutically active cells in a suitable medium, in particular produced using molecular biological, biotechnological and genetic methods;color is not claimed as a feature of the mark.;cell analyses in the nature of medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical and veterinary medical services, in particular extracting of blood and/or tissue samples and analysis and evaluation relating thereto; individualized medicine in the nature of medical services; medical services specifically, development of treatment plans for the treatment of tumors and/or neoplastic diseases, hematopoietic tumors, solid tumors; physical therapy adapted for individual patients;services in molecular biology, in particular research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological and genetic methods, and in the field of screening for compounds with pharmaceutical properties; development of test methods and test kits; development of adoptive t cell therapy; development of dc vaccines; development of cellular tumour therapy; development of tumour markers; development of diagnostic and therapeutic antibodies;.

Its status is currently believed to be active. Its class is unavailable. “MEDIGENE” is believed to be currently owned by “MEDIGENE AG”.